This article has received the support of the Spanish Network of Infectious Diseases (REIPI) and Spanish Group for the Study of Infection in Transplant patients (GESITRA). Dr Sanclemente has received a grant from the Hospital clinic and the Catalonian Society of Infectious Diseases and Clinical Microbiology (SCMIMC).
Incidence and outcome of early Candida peritonitis after liver and pancreas transplantation
Article first published online: 17 AUG 2012
© 2012 Blackwell Verlag GmbH
Volume 56, Issue 2, pages 162–167, March 2013
How to Cite
Bartoletti, M., Cervera, C., Hoyo, I., Linares, L., Sanclemente, G., Bosch, J., Marco, F., Cofán, F., Ricart, M. J., Navasa, M. and Moreno, A. (2013), Incidence and outcome of early Candida peritonitis after liver and pancreas transplantation. Mycoses, 56: 162–167. doi: 10.1111/j.1439-0507.2012.02227.x
- Issue published online: 26 FEB 2013
- Article first published online: 17 AUG 2012
- Submitted for publication 4 April 2012 Revised 15 June 2012 Accepted for publication 4 July 2012
- Candida spp.;
- antifungal agents
Candida peritonitis is a potentially life-threatening infection after abdominal transplantation, although there is scant information regarding its incidence and outcome. We analysed the incidence rate and outcome of Candida peritonitis in 717 liver or pancreas transplant recipients. Five cases of Candida peritonitis were diagnosed, representing the second most frequent cause of invasive fungal infection in the cohort. The incidence rate of Candida peritonitis during the first 30 days after transplantation was 6.5 cases/10 000 transplant days in pancreas recipients and 1.2 cases/10 000 transplant days in liver recipients (P = 0.035). Four of the five patients received an echinocandin in combination with other antifungal. All patients were alive and with good graft function at 1-year follow-up. In our series, Candida peritonitis in liver and pancreas transplant recipients was not uncommon and had a good prognosis.